Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks - 29/08/11
Tazarotene Cream Clinical Study Group*
Abstract |
Background: Tazarotene in a gel formulation is widely used in the treatment of psoriasis. Objective: To determine the efficacy and safety of tazarotene 0.1% and 0.05% creams in the treatment of psoriasis. Methods: A total of 1303 patients participated in 2 clinical trials. Patients applied tazarotene creams 0.1% and 0.05% or vehicle once daily to all psoriatic lesions for 12 weeks followed by a 12-week posttreatment period. Results: Both creams were significantly more effective than vehicle on the basis of an overall assessment of psoriasis, a global response to treatment, and reduction in plaque elevation and scaling. Therapeutic effect was maintained during the posttreatment period. Common adverse events included signs and symptoms of skin irritation. Conclusion: Tazarotene creams were associated with significant reductions in the severity of the clinical signs of psoriasis and were found to be safe with acceptable tolerability. Tazarotene cream 0.1% was generally more effective, although slightly less well tolerated, than the 0.05% cream. (J Am Acad Dermatol 2003;48:760-7.)
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: These studies were funded in their entirety by Allergan, Inc. |
| Disclosure: Drs Weinstein and Lowe are currently paid consultants to Allergan. Drs Koo, Krueger, Lebwohl, and Menter have at various times received honoraria for their participation as ad hoc consultants to Allergan and have received payments for their participation as investigators in clinical studies funded by Allergan. Drs Lew-Kaya, Sefton, Walker, and Gibson are Allergan employees. |
 | *Members of the Tazarotene Cream Clinical Study Group are listed at the end of the article. |
| Reprint requests: John Sefton, PhD, Allergan, Inc., 2525 Dupont Dr, Irvine, CA 92612-1599. E-mail: Sefton_John@Allergan.com. |
| ♢ | 0190-9622/2003/$30.00 + 0 |
Vol 48 - N° 5
P. 760-767 - mai 2003 Retour au numéro
Article précédent
- Transplants from balding and hairy androgenetic alopecia scalp regrow hair comparably well on immunodeficient mice
- Rozlyn A. Krajcik, Joseph H. Vogelman, Virginia L. Malloy, Norman Orentreich
- The new 940-nanometer diode laser: An effective treatment for leg venulectasia
- Thierry Passeron, Valérie Olivier, Luc Duteil, François Desruelles, Eric Fontas, Jean-Paul Ortonne
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?